{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T16:05:51Z","timestamp":1792425951754,"version":"4.5.0"},"reference-count":75,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2023,8,18]],"date-time":"2023-08-18T00:00:00Z","timestamp":1692316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,8,18]],"date-time":"2023-08-18T00:00:00Z","timestamp":1692316800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2024,2]]},"DOI":"10.1007\/s00280-023-04575-y","type":"journal-article","created":{"date-parts":[[2023,8,18]],"date-time":"2023-08-18T10:14:20Z","timestamp":1692353660000},"page":"89-105","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Mirvetuximab soravtansine in ovarian cancer therapy: expert opinion on pharmacological considerations"],"prefix":"10.1007","volume":"93","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1889-0334","authenticated-orcid":false,"given":"Chukwunonso K.","family":"Nwabufo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,8,18]]},"reference":[{"key":"4575_CR1","unstructured":"Food & Drug Administration Drug Approval Package: ELAHERE. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2022\/761310Orig1s000ChemR.pdf. Accessed 2 Apr 2023"},{"key":"4575_CR2","doi-asserted-by":"publisher","first-page":"123","DOI":"10.2217\/fon-2017-0379","volume":"14","author":"KN Moore","year":"2018","unstructured":"Moore KN, Martin LP, O\u2019Malley DM et al (2018) A review of mirvetuximab soravtansine in the treatment of platinum-resistant ovarian cancer. Future Oncol 14:123\u2013136. https:\/\/doi.org\/10.2217\/fon-2017-0379","journal-title":"Future Oncol"},{"key":"4575_CR3","doi-asserted-by":"publisher","first-page":"1605","DOI":"10.1158\/1535-7163.MCT-14-1095","volume":"14","author":"O Ab","year":"2015","unstructured":"Ab O, Whiteman KR, Bartle LM et al (2015) IMGN853, a folate receptor-\u03b1 (FR\u03b1)\u2013targeting antibody-drug conjugate, exhibits potent targeted antitumor activity against FR\u03b1 -expressing tumors. Mol Cancer Ther 14:1605\u20131613. https:\/\/doi.org\/10.1158\/1535-7163.MCT-14-1095","journal-title":"Mol Cancer Ther"},{"key":"4575_CR4","doi-asserted-by":"crossref","unstructured":"Joubert N, Beck A, Dumontet C, Denevault-Sabourin C (2020) Antibody\u2013Drug Conjugates: The Last Decade. Pharmaceuticals 13:245. https:\/\/doi.org\/10.3390\/ph13090245","DOI":"10.3390\/ph13090245"},{"key":"4575_CR5","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1111\/bcp.12044","volume":"76","author":"JM Lambert","year":"2013","unstructured":"Lambert JM (2013) Drug-conjugated antibodies for the treatment of cancer: antibody-drug conjugates. Br J Clin Pharmacol 76:248\u2013262. https:\/\/doi.org\/10.1111\/bcp.12044","journal-title":"Br J Clin Pharmacol"},{"key":"4575_CR6","doi-asserted-by":"publisher","first-page":"2358","DOI":"10.1158\/0008-5472.CAN-08-2250","volume":"69","author":"AG Polson","year":"2009","unstructured":"Polson AG, Calemine-Fenaux J, Chan P et al (2009) Antibody-drug conjugates for the treatment of non\u2013hodgkin\u2019s lymphoma: target and linker-drug selection. Can Res 69:2358\u20132364. https:\/\/doi.org\/10.1158\/0008-5472.CAN-08-2250","journal-title":"Can Res"},{"key":"4575_CR7","doi-asserted-by":"publisher","first-page":"4392","DOI":"10.1021\/jm060319f","volume":"49","author":"WC Widdison","year":"2006","unstructured":"Widdison WC, Wilhelm SD, Cavanagh EE et al (2006) Semisynthetic maytansine analogues for the targeted treatment of cancer. J Med Chem 49:4392\u20134408. https:\/\/doi.org\/10.1021\/jm060319f","journal-title":"J Med Chem"},{"key":"4575_CR8","doi-asserted-by":"publisher","first-page":"2700","DOI":"10.1158\/1535-7163.MCT-10-0645","volume":"9","author":"E Oroudjev","year":"2010","unstructured":"Oroudjev E, Lopus M, Wilson L et al (2010) Maytansinoid-antibody conjugates induce mitotic arrest by suppressing microtubule dynamic instability. Mol Cancer Ther 9:2700\u20132713. https:\/\/doi.org\/10.1158\/1535-7163.MCT-10-0645","journal-title":"Mol Cancer Ther"},{"key":"4575_CR9","doi-asserted-by":"publisher","unstructured":"Goldmacher VS, Audette CA, Guan Y, et al (2015) High-Affinity Accumulation of a Maytansinoid in Cells via Weak Tubulin Interaction. PLoS ONE 10:e0117523. https:\/\/doi.org\/10.1371\/journal.pone.0117523","DOI":"10.1371\/journal.pone.0117523"},{"key":"4575_CR10","doi-asserted-by":"publisher","unstructured":"Nerone M, Del Grande M, Sessa C, Colombo I (2022) Advancing antibody-drug conjugates in gynecological malignancies: myth or reality? Exploration of Targeted Anti-tumor Therapy 149\u2013171. https:\/\/doi.org\/10.37349\/etat.2022.00077","DOI":"10.37349\/etat.2022.00077"},{"key":"4575_CR11","unstructured":"Food & Drug Administration FDA grants accelerated approval to mirvetuximab soravtansine-gynx for FR\u03b1 positive, platinum-resistant epithelial ovarian, fallopian tube, or peritoneal cancer. https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-grants-accelerated-approval-mirvetuximab-soravtansine-gynx-fra-positive-platinum-resistant. Accessed 31 Mar 2023"},{"key":"4575_CR12","unstructured":"Roche Roche receives FDA approval for VENTANA FOLR1 (FOLR1\u20132.1) RxDx Assay as the first IHC-based companion diagnostic to identify ovarian cancer patients eligible for ELAHERE. https:\/\/diagnostics.roche.com\/us\/en\/news-listing\/2022\/roche-fda-approval-for-ventana-folr1-folr121-rxdx-assay.html. Accessed 31 Mar 2023"},{"key":"4575_CR13","unstructured":"Roche VENTANA FOLR1 (FOLR1\u20132.1) RxDx Assay label. 2022. https:\/\/www.accessdata.fda.gov\/cdrh_docs\/pdf22\/P220006C.pdf. Accessed 31 Mar 2023"},{"key":"4575_CR14","unstructured":"ImmunoGen ElahereTM (mirvetuximab soravtansine-gynx) injection, for intravenous use. 2022. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/761310s000lbl.pdf. Accessed 31 Mar 2023"},{"key":"4575_CR15","doi-asserted-by":"publisher","unstructured":"Matulonis UA, Lorusso D, Oaknin A, et al (2023) Efficacy and Safety of Mirvetuximab Soravtansine in Patients With Platinum-Resistant Ovarian Cancer With High Folate Receptor Alpha Expression: Results From the SORAYA Study. JCO JCO.22.01900. https:\/\/doi.org\/10.1200\/JCO.22.01900","DOI":"10.1200\/JCO.22.01900"},{"key":"4575_CR16","doi-asserted-by":"publisher","first-page":"S50","DOI":"10.1016\/S0090-8258(22)01297-5","volume":"166","author":"U Matulonis","year":"2022","unstructured":"Matulonis U, Lorusso D, Oaknin A et al (2022) Efficacy and safety of mirvetuximab soravtansine in patients with platinum-resistant ovarian cancer with high folate receptor alpha expression: results from the SORAYA study (LBA 4). Gynecol Oncol 166:S50. https:\/\/doi.org\/10.1016\/S0090-8258(22)01297-5","journal-title":"Gynecol Oncol"},{"key":"4575_CR17","doi-asserted-by":"crossref","unstructured":"Coleman RL, Matulonis U, Lorusso D, et al (2022) O028\/#376 Clinical benefit of mirvetuximab soravtansine in ovarian cancer patients with high folate receptor alpha expression: results from the soraya study. In: Focused Plenary Abstracts. BMJ Publishing Group Ltd, p A18.1-A18","DOI":"10.1136\/ijgc-2022-igcs.30"},{"key":"4575_CR18","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1016\/j.neo.2016.11.002","volume":"18","author":"JF Ponte","year":"2016","unstructured":"Ponte JF, Ab O, Lanieri L et al (2016) Mirvetuximab soravtansine (IMGN853), a folate receptor alpha-targeting antibody-drug conjugate, potentiates the activity of standard of care therapeutics in ovarian cancer models. Neoplasia 18:775\u2013784. https:\/\/doi.org\/10.1016\/j.neo.2016.11.002","journal-title":"Neoplasia"},{"key":"4575_CR19","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1007\/s40265-023-01834-3","volume":"83","author":"Y-A Heo","year":"2023","unstructured":"Heo Y-A (2023) Mirvetuximab soravtansine: first approval. Drugs 83:265\u2013273. https:\/\/doi.org\/10.1007\/s40265-023-01834-3","journal-title":"Drugs"},{"key":"4575_CR20","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1016\/j.ygyno.2017.08.015","volume":"147","author":"LP Martin","year":"2017","unstructured":"Martin LP, Konner JA, Moore KN et al (2017) Characterization of folate receptor alpha (FR\u03b1) expression in archival tumor and biopsy samples from relapsed epithelial ovarian cancer patients: a phase I expansion study of the FR\u03b1-targeting antibody-drug conjugate mirvetuximab soravtansine. Gynecol Oncol 147:402\u2013407. https:\/\/doi.org\/10.1016\/j.ygyno.2017.08.015","journal-title":"Gynecol Oncol"},{"key":"4575_CR21","doi-asserted-by":"publisher","first-page":"4426","DOI":"10.1158\/0008-5472.CAN-05-4489","volume":"66","author":"HK Erickson","year":"2006","unstructured":"Erickson HK, Park PU, Widdison WC et al (2006) Antibody-maytansinoid conjugates are activated in targeted cancer cells by lysosomal degradation and linker-dependent intracellular processing. Can Res 66:4426\u20134433. https:\/\/doi.org\/10.1158\/0008-5472.CAN-05-4489","journal-title":"Can Res"},{"key":"4575_CR22","doi-asserted-by":"publisher","first-page":"3214","DOI":"10.1158\/0008-5472.CAN-05-3973","volume":"66","author":"YV Kovtun","year":"2006","unstructured":"Kovtun YV, Audette CA, Ye Y et al (2006) Antibody-drug conjugates designed to eradicate tumors with homogeneous and heterogeneous expression of the target antigen. Can Res 66:3214\u20133221. https:\/\/doi.org\/10.1158\/0008-5472.CAN-05-3973","journal-title":"Can Res"},{"key":"4575_CR23","first-page":"2328","volume":"41","author":"B Drewinko","year":"1981","unstructured":"Drewinko B, Patchen M, Yang LY, Barlogie B (1981) Differential killing efficacy of twenty antitumor drugs on proliferating and nonproliferating human tumor cells. Cancer Res 41:2328\u20132333","journal-title":"Cancer Res"},{"key":"4575_CR24","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1158\/1535-7163.MCT-17-0930","volume":"17","author":"G Altwerger","year":"2018","unstructured":"Altwerger G, Bonazzoli E, Bellone S et al (2018) In Vitro and In Vivo Activity of IMGN853, an antibody-drug conjugate targeting folate receptor alpha linked to DM4, in biologically aggressive endometrial cancers. Mol Cancer Ther 17:1003\u20131011. https:\/\/doi.org\/10.1158\/1535-7163.MCT-17-0930","journal-title":"Mol Cancer Ther"},{"key":"4575_CR25","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.1158\/1538-7445.AM2020-1237","volume":"80","author":"A Chelariu-Raicu","year":"2020","unstructured":"Chelariu-Raicu A, Stur E, Ivan C et al (2020) Abstract 1237: biological effects of a FR\u03b1-targeting antibody-drug conjugate, IMGN853 ( mirvetuximab soravtansine ) in high-grade serous ovarian cancer. Can Res 80:1237\u20131237. https:\/\/doi.org\/10.1158\/1538-7445.AM2020-1237","journal-title":"Can Res"},{"key":"4575_CR26","doi-asserted-by":"publisher","first-page":"S822","DOI":"10.1016\/j.annonc.2022.07.733","volume":"33","author":"KN Moore","year":"2022","unstructured":"Moore KN, Lorusso D, Oaknin A et al (2022) 605P Population pharmacokinetic (PK) analysis of mirvetuximab soravtansine (MIRV) in patients with folate receptor \u03b1 (FR\u03b1)-positive cancer. Ann Oncol 33:S822\u2013S823. https:\/\/doi.org\/10.1016\/j.annonc.2022.07.733","journal-title":"Ann Oncol"},{"key":"4575_CR27","doi-asserted-by":"publisher","unstructured":"Moore KN, Angelergues A, Konecny GE, et al (2023) Phase III MIRASOL (GOG 3045\/ENGOT-ov55) study: Initial report of mirvetuximab soravtansine vs. investigator\u2019s choice of chemotherapy in platinum-resistant, advanced high-grade epithelial ovarian, primary peritoneal, or fallopian tube cancers with high folate receptor-alpha expression. JCO 41:LBA5507\u2013LBA5507. https:\/\/doi.org\/10.1200\/JCO.2023.41.17_suppl.LBA5507","DOI":"10.1200\/JCO.2023.41.17_suppl.LBA5507"},{"key":"4575_CR28","doi-asserted-by":"publisher","first-page":"4361","DOI":"10.1039\/C8CS00676H","volume":"48","author":"JD Bargh","year":"2019","unstructured":"Bargh JD, Isidro-Llobet A, Parker JS, Spring DR (2019) Cleavable linkers in antibody\u2013drug conjugates. Chem Soc Rev 48:4361\u20134374. https:\/\/doi.org\/10.1039\/C8CS00676H","journal-title":"Chem Soc Rev"},{"key":"4575_CR29","doi-asserted-by":"publisher","first-page":"1705","DOI":"10.3390\/pharmaceutics13101705","volume":"13","author":"C Mart\u00edn-Sabroso","year":"2021","unstructured":"Mart\u00edn-Sabroso C, Lozza I, Torres-Su\u00e1rez AI, Fraguas-S\u00e1nchez AI (2021) Antibody-antineoplastic conjugates in gynecological malignancies: current status and future perspectives. Pharmaceutics 13:1705. https:\/\/doi.org\/10.3390\/pharmaceutics13101705","journal-title":"Pharmaceutics"},{"key":"4575_CR30","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1016\/j.ejpb.2019.03.021","volume":"139","author":"C Duerr","year":"2019","unstructured":"Duerr C, Friess W (2019) Antibody-drug conjugates- stability and formulation. Eur J Pharm Biopharm 139:168\u2013176. https:\/\/doi.org\/10.1016\/j.ejpb.2019.03.021","journal-title":"Eur J Pharm Biopharm"},{"key":"4575_CR31","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1016\/j.ajhg.2009.08.005","volume":"85","author":"R Steinfeld","year":"2009","unstructured":"Steinfeld R, Grapp M, Kraetzner R et al (2009) Folate receptor alpha defect causes cerebral folate transport deficiency: a treatable neurodegenerative disorder associated with disturbed myelin metabolism. The American Journal of Human Genetics 85:354\u2013363. https:\/\/doi.org\/10.1016\/j.ajhg.2009.08.005","journal-title":"The American Journal of Human Genetics"},{"key":"4575_CR32","doi-asserted-by":"publisher","first-page":"e180","DOI":"10.1634\/theoncologist.2019-0098","volume":"24","author":"NC Richardson","year":"2019","unstructured":"Richardson NC, Kasamon YL, Chen H et al (2019) FDA approval summary: brentuximab vedotin in first-line treatment of peripheral T-cell lymphoma. Oncologist 24:e180\u2013e187. https:\/\/doi.org\/10.1634\/theoncologist.2019-0098","journal-title":"Oncologist"},{"key":"4575_CR33","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1016\/S0140-6736(17)31266-7","volume":"390","author":"HM Prince","year":"2017","unstructured":"Prince HM, Kim YH, Horwitz SM et al (2017) Brentuximab vedotin or physician\u2019s choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial. The Lancet 390:555\u2013566. https:\/\/doi.org\/10.1016\/S0140-6736(17)31266-7","journal-title":"The Lancet"},{"key":"4575_CR34","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1080\/13543784.2020.1792443","volume":"29","author":"R Bartsch","year":"2020","unstructured":"Bartsch R (2020) Trastuzumab-deruxtecan: an investigational agent for the treatment of HER2-positive breast cancer. Expert Opin Investig Drugs 29:901\u2013910. https:\/\/doi.org\/10.1080\/13543784.2020.1792443","journal-title":"Expert Opin Investig Drugs"},{"key":"4575_CR35","doi-asserted-by":"publisher","first-page":"434","DOI":"10.2174\/1389200223666220621113524","volume":"23","author":"CK Nwabufo","year":"2022","unstructured":"Nwabufo CK (2022) Relevance of ABC transporters in drug development. Curr Drug Metab 23:434\u2013446. https:\/\/doi.org\/10.2174\/1389200223666220621113524","journal-title":"Curr Drug Metab"},{"key":"4575_CR36","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-022-11267-9","author":"CK Nwabufo","year":"2022","unstructured":"Nwabufo CK, Aigbogun OP (2022) Diagnostic and therapeutic agents that target alpha - synuclein in Parkinson \u2019 s disease. J Neurol. https:\/\/doi.org\/10.1007\/s00415-022-11267-9","journal-title":"J Neurol"},{"key":"4575_CR37","doi-asserted-by":"publisher","unstructured":"Hoosain FG, Choonara YE, Tomar LK, et al (2015) Bypassing P-Glycoprotein Drug Efflux Mechanisms: Possible Applications in Pharmacoresistant Schizophrenia Therapy. Biomed Res Int 2015:484963. https:\/\/doi.org\/10.1155\/2015\/484963","DOI":"10.1155\/2015\/484963"},{"key":"4575_CR38","unstructured":"US Food and Drug Administration (2019) Immunogenicity Testing of Therapeutic Protein Products\u2014Developing and Validating Assays for Anti-Drug Antibody Detection Guidance for Industry. https:\/\/www.fda.gov\/media\/119788\/download. Accessed 28 Jul 2023"},{"key":"4575_CR39","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.clim.2005.08.017","volume":"118","author":"MDFS Barbosa","year":"2006","unstructured":"Barbosa MDFS, Vielmetter J, Chu S et al (2006) Clinical link between MHC class II haplotype and interferon-beta (IFN-\u03b2) immunogenicity. Clin Immunol 118:42\u201350. https:\/\/doi.org\/10.1016\/j.clim.2005.08.017","journal-title":"Clin Immunol"},{"key":"4575_CR40","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1208\/s12248-012-9340-y","volume":"14","author":"N Chirmule","year":"2012","unstructured":"Chirmule N, Jawa V, Meibohm B (2012) Immunogenicity to therapeutic proteins: impact on PK\/PD and efficacy. AAPS J 14:296\u2013302. https:\/\/doi.org\/10.1208\/s12248-012-9340-y","journal-title":"AAPS J"},{"key":"4575_CR41","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2016\/1298473","volume":"2016","author":"A Kuriakose","year":"2016","unstructured":"Kuriakose A, Chirmule N, Nair P (2016) Immunogenicity of biotherapeutics: causes and association with posttranslational modifications. J Immunol Res 2016:1\u201318. https:\/\/doi.org\/10.1155\/2016\/1298473","journal-title":"J Immunol Res"},{"key":"4575_CR42","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1046\/j.1365-2516.1999.00300.x","volume":"5","author":"B Scharrer","year":"1999","unstructured":"Scharrer B, Neutzling, (1999) Incidence of inhibitors in haemophilia A patients - a review of recent studies of recombinant and plasma-derived factor VIII concentrates: INCIDENCE OF INHIBITORS IN HAEMOPHILIA A. Haemophilia 5:145\u2013154. https:\/\/doi.org\/10.1046\/j.1365-2516.1999.00300.x","journal-title":"Haemophilia"},{"key":"4575_CR43","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1016\/j.nbt.2009.03.012","volume":"25","author":"E-M Jahn","year":"2009","unstructured":"Jahn E-M, Schneider CK (2009) How to systematically evaluate immunogenicity of therapeutic proteins\u2014regulatory considerations. New Biotechnol 25:280\u2013286. https:\/\/doi.org\/10.1016\/j.nbt.2009.03.012","journal-title":"New Biotechnol"},{"key":"4575_CR44","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1002\/cpt.2432","volume":"112","author":"A-CD Dunvald","year":"2022","unstructured":"Dunvald A-CD, J\u00e4rvinen E, Mortensen C, Stage TB (2022) Clinical and molecular perspectives on inflammation-mediated regulation of drug metabolism and transport. Clin Pharmacol Ther 112:277\u2013290. https:\/\/doi.org\/10.1002\/cpt.2432","journal-title":"Clin Pharmacol Ther"},{"key":"4575_CR45","doi-asserted-by":"publisher","unstructured":"Stanke-Labesque F, Gautier-Veyret E, Chhun S, et al (2020) Inflammation is a major regulator of drug metabolizing enzymes and transporters: Consequences for the personalization of drug treatment. Pharmacol Ther 215:107627. https:\/\/doi.org\/10.1016\/j.pharmthera.2020.107627","DOI":"10.1016\/j.pharmthera.2020.107627"},{"key":"4575_CR46","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.jfda.2018.11.005","volume":"27","author":"K-C Wu","year":"2019","unstructured":"Wu K-C, Lin C-J (2019) The regulation of drug-metabolizing enzymes and membrane transporters by inflammation: evidences in inflammatory diseases and age-related disorders. J Food Drug Anal 27:48\u201359. https:\/\/doi.org\/10.1016\/j.jfda.2018.11.005","journal-title":"J Food Drug Anal"},{"key":"4575_CR47","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1016\/j.tips.2022.09.005","volume":"43","author":"CK Nwabufo","year":"2022","unstructured":"Nwabufo CK, Bendayan R (2022) Pharmacokinetic considerations to optimize clinical outcomes for COVID-19 drugs. Trends Pharmacol Sci 43:1041\u20131054. https:\/\/doi.org\/10.1016\/j.tips.2022.09.005","journal-title":"Trends Pharmacol Sci"},{"key":"4575_CR48","doi-asserted-by":"publisher","first-page":"1124693","DOI":"10.3389\/fphar.2023.1124693","volume":"14","author":"CK Nwabufo","year":"2023","unstructured":"Nwabufo CK, Hoque MdT, Yip L et al (2023) SARS-CoV-2 infection dysregulates the expression of clinically relevant drug metabolizing enzymes in Vero E6 cells and membrane transporters in human lung tissues. Front Pharmacol 14:1124693. https:\/\/doi.org\/10.3389\/fphar.2023.1124693","journal-title":"Front Pharmacol"},{"key":"4575_CR49","doi-asserted-by":"publisher","first-page":"3712","DOI":"10.1111\/bph.14776","volume":"176","author":"S Trousil","year":"2019","unstructured":"Trousil S, Lee P, Edwards RJ et al (2019) Altered cytochrome 2E1 and 3A P450-dependent drug metabolism in advanced ovarian cancer correlates to tumour-associated inflammation. Br J Pharmacol 176:3712\u20133722. https:\/\/doi.org\/10.1111\/bph.14776","journal-title":"Br J Pharmacol"},{"key":"4575_CR50","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1038\/sj.bjc.6600448","volume":"87","author":"LP Rivory","year":"2002","unstructured":"Rivory LP, Slaviero KA, Clarke SJ (2002) Hepatic cytochrome P450 3A drug metabolism is reduced in cancer patients who have an acute-phase response. Br J Cancer 87:277\u2013280. https:\/\/doi.org\/10.1038\/sj.bjc.6600448","journal-title":"Br J Cancer"},{"key":"4575_CR51","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1016\/S1470-2045(03)01034-9","volume":"4","author":"KA Slaviero","year":"2003","unstructured":"Slaviero KA, Clarke SJ, Rivory LP (2003) Inflammatory response: an unrecognised source of variability in the pharmacokinetics and pharmacodynamics of cancer chemotherapy. Lancet Oncol 4:224\u2013232. https:\/\/doi.org\/10.1016\/S1470-2045(03)01034-9","journal-title":"Lancet Oncol"},{"key":"4575_CR52","doi-asserted-by":"publisher","unstructured":"Lee EB, Daskalakis N, Xu C, et al (2017) Disease\u2013Drug Interaction of Sarilumab and Simvastatin in Patients with Rheumatoid Arthritis. Clinical Pharmacokinetics 56:. https:\/\/doi.org\/10.1007\/s40262-016-0462-8","DOI":"10.1007\/s40262-016-0462-8"},{"key":"4575_CR53","doi-asserted-by":"publisher","unstructured":"Schmitt C, Kuhn B, Zhang X, et al (2011) Disease-drug-drug interaction involving tocilizumab and simvastatin in patients with rheumatoid arthritis. Clin Pharmacol Therapeutics 89:. https:\/\/doi.org\/10.1038\/clpt.2011.35","DOI":"10.1038\/clpt.2011.35"},{"key":"4575_CR54","doi-asserted-by":"publisher","unstructured":"Zhuang Y, De Vries DE, Xu Z, et al (2015) Evaluation of disease-mediated therapeutic protein-drug interactions between an anti-interleukin-6 monoclonal antibody (sirukumab) and cytochrome P450 activities in a phase 1 study in patients with rheumatoid arthritis using a cocktail approach. J Clin Pharmacol 55:. https:\/\/doi.org\/10.1002\/jcph.561","DOI":"10.1002\/jcph.561"},{"key":"4575_CR55","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/s13048-021-00787-z","volume":"14","author":"S Chaudhari","year":"2021","unstructured":"Chaudhari S, Dey Pereira S, Asare-Warehene M et al (2021) Comorbidities and inflammation associated with ovarian cancer and its influence on SARS-CoV-2 infection. J Ovarian Res 14:39. https:\/\/doi.org\/10.1186\/s13048-021-00787-z","journal-title":"J Ovarian Res"},{"key":"4575_CR56","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1038\/s41392-020-0211-1","volume":"5","author":"Z-S Xu","year":"2020","unstructured":"Xu Z-S, Shu T, Kang L et al (2020) Temporal profiling of plasma cytokines, chemokines and growth factors from mild, severe and fatal COVID-19 patients. Sig Transduct Target Ther 5:100. https:\/\/doi.org\/10.1038\/s41392-020-0211-1","journal-title":"Sig Transduct Target Ther"},{"key":"4575_CR57","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1016\/S2213-2600(20)30076-X","volume":"8","author":"Z Xu","year":"2020","unstructured":"Xu Z, Shi L, Wang Y et al (2020) Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir Med 8:420\u2013422. https:\/\/doi.org\/10.1016\/S2213-2600(20)30076-X","journal-title":"Lancet Respir Med"},{"key":"4575_CR58","doi-asserted-by":"publisher","unstructured":"Liu J, Li S, Liu J, et al (2020) Longitudinal characteristics of lymphocyte responses and cytokine profiles in the peripheral blood of SARS-CoV-2 infected patients. EBioMedicine 55:102763. https:\/\/doi.org\/10.1016\/j.ebiom.2020.102763","DOI":"10.1016\/j.ebiom.2020.102763"},{"key":"4575_CR59","doi-asserted-by":"publisher","unstructured":"Huang C, Wang Y, Li X, et al (2020) Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. The Lancet 395:. https:\/\/doi.org\/10.1016\/S0140-6736(20)30183-5","DOI":"10.1016\/S0140-6736(20)30183-5"},{"key":"4575_CR60","doi-asserted-by":"crossref","unstructured":"Yang Y, Shen C, Li J, et al (2020) Exuberant elevation of IP-10, MCP-3 and IL-1ra during SARS-CoV-2 infection is associated with disease severity and fatal outcome. Infectious Dis (except HIV\/AIDS)","DOI":"10.1101\/2020.03.02.20029975"},{"key":"4575_CR61","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/j.jaci.2020.04.006","volume":"146","author":"X Li","year":"2020","unstructured":"Li X, Xu S, Yu M et al (2020) Risk factors for severity and mortality in adult COVID-19 inpatients in Wuhan. J Allergy Clin Immunol 146:110\u2013118. https:\/\/doi.org\/10.1016\/j.jaci.2020.04.006","journal-title":"J Allergy Clin Immunol"},{"key":"4575_CR62","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1158\/1055-9965.EPI-04-0404","volume":"14","author":"E Gorelik","year":"2005","unstructured":"Gorelik E, Landsittel DP, Marrangoni AM et al (2005) Multiplexed immunobead-based cytokine profiling for early detection of ovarian cancer. Cancer Epidemiol Biomark Prev 14:981\u2013987. https:\/\/doi.org\/10.1158\/1055-9965.EPI-04-0404","journal-title":"Cancer Epidemiol Biomark Prev"},{"key":"4575_CR63","doi-asserted-by":"publisher","first-page":"18503","DOI":"10.1038\/s41598-020-75536-1","volume":"10","author":"A Yabuno","year":"2020","unstructured":"Yabuno A, Matsushita H, Hamano T et al (2020) Identification of serum cytokine clusters associated with outcomes in ovarian clear cell carcinoma. Sci Rep 10:18503. https:\/\/doi.org\/10.1038\/s41598-020-75536-1","journal-title":"Sci Rep"},{"key":"4575_CR64","doi-asserted-by":"publisher","first-page":"2702","DOI":"10.1093\/jac\/dkaa195","volume":"75","author":"M Gregoire","year":"2020","unstructured":"Gregoire M, Le Turnier P, Gaborit BJ et al (2020) Lopinavir pharmacokinetics in COVID-19 patients. J Antimicrob Chemother 75:2702\u20132704. https:\/\/doi.org\/10.1093\/jac\/dkaa195","journal-title":"J Antimicrob Chemother"},{"key":"4575_CR65","doi-asserted-by":"publisher","unstructured":"Salerno DM, Kovac D, Corbo H, et al (2021) SARS-CoV-2 infection increases tacrolimus concentrations in solid-organ transplant recipients. Clin Transplant 35:e14193. https:\/\/doi.org\/10.1111\/ctr.14193","DOI":"10.1111\/ctr.14193"},{"key":"4575_CR66","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1002\/cpt.2698","volume":"112","author":"EC Le Carpentier","year":"2022","unstructured":"Le Carpentier EC, Canet E, Masson D et al (2022) Impact of Inflammation on Midazolam Metabolism in Severe COVID-19 Patients. Clin Pharmacol Ther 112:1033\u20131039. https:\/\/doi.org\/10.1002\/cpt.2698","journal-title":"Clin Pharmacol Ther"},{"key":"4575_CR67","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1111\/bcpt.13780","volume":"131","author":"DB Iversen","year":"2022","unstructured":"Iversen DB, Andersen NE, Dalg\u00e5rd Dunvald A et al (2022) Drug metabolism and drug transport of the 100 most prescribed oral drugs. Basic Clin Pharma Tox 131:311\u2013324. https:\/\/doi.org\/10.1111\/bcpt.13780","journal-title":"Basic Clin Pharma Tox"},{"key":"4575_CR68","first-page":"1","volume":"1","author":"US Food and Drug Administration","year":"2020","unstructured":"US Food and Drug Administration (2020) In Vitro Drug Interaction Studies - Cytochrome P450 Enzyme and Transporter Mediated Drug Interactions. FDA Guidance 1:1\u201346","journal-title":"FDA Guidance"},{"key":"4575_CR69","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.ygyno.2018.07.017","volume":"151","author":"KN Moore","year":"2018","unstructured":"Moore KN, O\u2019Malley DM, Vergote I et al (2018) Safety and activity findings from a phase 1b escalation study of mirvetuximab soravtansine, a folate receptor alpha (FR\u03b1)-targeting antibody-drug conjugate (ADC), in combination with carboplatin in patients with platinum-sensitive ovarian cancer. Gynecol Oncol 151:46\u201352. https:\/\/doi.org\/10.1016\/j.ygyno.2018.07.017","journal-title":"Gynecol Oncol"},{"key":"4575_CR70","doi-asserted-by":"publisher","first-page":"v419","DOI":"10.1093\/annonc\/mdz250.036","volume":"30","author":"D O\u2019Malley","year":"2019","unstructured":"O\u2019Malley D, Richardson D, Vergote IB et al (2019) Mirvetuximab soravtansine, a folate receptor alpha (FRa)-targeting antibody-drug conjugate (ADC), in combination with carboplatin and bevacizumab: Initial results from a phase Ib study in patients (pts) with ovarian cancer. Ann Oncol 30:v419\u2013v420. https:\/\/doi.org\/10.1093\/annonc\/mdz250.036","journal-title":"Ann Oncol"},{"key":"4575_CR71","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1016\/j.ygyno.2020.01.037","volume":"157","author":"DM O\u2019Malley","year":"2020","unstructured":"O\u2019Malley DM, Matulonis UA, Birrer MJ et al (2020) Phase Ib study of mirvetuximab soravtansine, a folate receptor alpha (FR\u03b1)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients with platinum-resistant ovarian cancer. Gynecol Oncol 157:379\u2013385. https:\/\/doi.org\/10.1016\/j.ygyno.2020.01.037","journal-title":"Gynecol Oncol"},{"key":"4575_CR72","doi-asserted-by":"publisher","first-page":"5504","DOI":"10.1200\/JCO.2021.39.15_suppl.5504","volume":"39","author":"DM O\u2019Malley","year":"2021","unstructured":"O\u2019Malley DM, Oaknin A, Matulonis UA et al (2021) Mirvetuximab soravtansine, a folate receptor alpha (FR\u03b1)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients (pts) with platinum-agnostic ovarian cancer: Final analysis. JCO 39:5504\u20135504. https:\/\/doi.org\/10.1200\/JCO.2021.39.15_suppl.5504","journal-title":"JCO"},{"key":"4575_CR73","doi-asserted-by":"publisher","first-page":"3080","DOI":"10.1002\/cncr.30736","volume":"123","author":"KN Moore","year":"2017","unstructured":"Moore KN, Borghaei H, O\u2019Malley DM et al (2017) Phase 1 dose-escalation study of mirvetuximab soravtansine (IMGN853), a folate receptor \u03b1-targeting antibody-drug conjugate, in patients with solid tumors: Mirvetuximab Soravtansine Phase 1 Study. Cancer 123:3080\u20133087. https:\/\/doi.org\/10.1002\/cncr.30736","journal-title":"Cancer"},{"key":"4575_CR74","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1016\/j.annonc.2021.02.017","volume":"32","author":"KN Moore","year":"2021","unstructured":"Moore KN, Oza AM, Colombo N et al (2021) Phase III, randomized trial of mirvetuximab soravtansine versus chemotherapy in patients with platinum-resistant ovarian cancer: primary analysis of FORWARD I. Ann Oncol 32:757\u2013765. https:\/\/doi.org\/10.1016\/j.annonc.2021.02.017","journal-title":"Ann Oncol"},{"key":"4575_CR75","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/j.ygyno.2023.01.020","volume":"170","author":"L Gilbert","year":"2023","unstructured":"Gilbert L, Oaknin A, Matulonis UA et al (2023) Safety and efficacy of mirvetuximab soravtansine, a folate receptor alpha (FR\u03b1)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients with platinum-resistant ovarian cancer. Gynecol Oncol 170:241\u2013247. https:\/\/doi.org\/10.1016\/j.ygyno.2023.01.020","journal-title":"Gynecol Oncol"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-023-04575-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00280-023-04575-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-023-04575-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,8]],"date-time":"2024-02-08T05:03:25Z","timestamp":1707368605000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00280-023-04575-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,18]]},"references-count":75,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,2]]}},"alternative-id":["4575"],"URL":"https:\/\/doi.org\/10.1007\/s00280-023-04575-y","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"value":"0344-5704","type":"print"},{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,18]]},"assertion":[{"value":"5 June 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 August 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 August 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"CKN was a former employee of Gilead Sciences. CKN is employed by OneDrug.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}